Chinook Therapeutics, Inc. (KDNY) Financials

NASDAQ Currency in USD Disclaimer

$40.39

north_east NA Past Year
Day's range
$40.3
Day's range
$40.51
$100M$100M$50M$50M$0$0-$50M-$50M-$100M-$100M-$150M-$150M-$200M-$200MEarning201620162017201720182018201920192020202020212021202220220%0%-2000%-2000%-4000%-4000%-6000%-6000%-8000%-8000%-10000%-10000%-12000%-12000%Profit Margin
Profit Margin
Revenue
Earnings

KDNY Income statement / Annual

Last year (2022), Chinook Therapeutics, Inc.'s total revenue was $6.13 M, a decrease of 88.13% from the previous year. In 2022, Chinook Therapeutics, Inc.'s net income was -$184.62 M. See Chinook Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015
Period Ended 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Operating Revenue $6.13 M $51.63 M $827,000.00 $17.26 M $15.09 M $17.24 M $50.68 M $72.98 M
Cost of Revenue $1.72 M $1.69 M $422,000.00 $554,000.00 $584,000.00 $559,000.00 $549,000.00 $89,000.00
Gross Profit $4.41 M $49.94 M $405,000.00 $16.70 M $14.50 M $16.68 M $50.13 M $72.89 M
Gross Profit Ratio 0.72 0.97 0.49 0.97 0.96 0.97 0.99 1
Research and Development Expenses $141.21 M $96.99 M $36.05 M $17.01 M $75.84 M $89.38 M $87.72 M $58.65 M
General & Administrative Expenses $36.29 M $31.90 M $19.07 M $2.96 M $36.04 M $33.75 M $34.28 M $27.81 M
Selling & Marketing Expenses $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Selling, General & Administrative Expenses $36.29 M $31.90 M $19.07 M $2.96 M $36.04 M $33.75 M $34.28 M $27.81 M
Other Expenses $1.72 M $1.69 M $422,000.00 $299,000.00 $3.99 M $0.00 $0.00 $0.00
Operating Expenses $179.22 M $130.57 M $55.54 M $19.97 M $115.86 M $123.13 M $122.00 M $86.45 M
Cost And Expenses $179.22 M $130.57 M $55.54 M $19.97 M $116.45 M $123.69 M $122.54 M $86.54 M
Interest Income $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Interest Expense $7.18 M $0.00 $15,000.00 $33,000.00 $0.00 $0.00 $2.22 M $494,000.00
Depreciation & Amortization $20.89 M $41.87 M $2.25 M $520,000.00 $4.95 M $3.99 M $2.55 M $0.00
EBITDA -$164.20 M -$57.17 M -$53.98 M -$19.45 M -$101.36 M -$106.45 M -$71.86 M -$13.56 M
EBITDA Ratio -26.79 -1.11 -65.27 -1.13 -6.72 -6.18 -1.42 -0.19
Operating Income Ratio -30.2 -1.92 -67.99 -1.16 -6.72 -6.18 -1.42 -0.19
Total Other Income/Expenses Net $4.81 M -$170,000.00 -$27.40 M -$64.82 M $5.22 M $3.23 M $2.18 M -$25.74 M
Income Before Tax -$180.27 M -$99.21 M -$83.63 M -$46.52 M -$96.14 M -$103.23 M -$69.68 M -$39.31 M
Income Before Tax Ratio -29.42 -1.92 -101.12 -2.7 -6.37 -5.99 -1.37 -0.54
Income Tax Expense $4.34 M $2.09 M -$2.00 M $332,000.00 $783,000.00 $11.36 M -$21.46 M -$99,000.00
Net Income -$184.62 M -$101.30 M -$81.62 M -$46.85 M -$95.36 M -$91.86 M -$91.15 M -$39.21 M
Net Income Ratio -30.13 -1.96 -98.7 -2.71 -6.32 -5.33 -1.8 -0.54
EPS -2.87 -2.22 -6.2 -1.11 -0.0012 -0.0013 -0.0014 -0.0009
EPS Diluted -2.87 -2.22 -6.2 -1.11 -0.0012 -0.0013 -0.0014 -0.0009
Weighted Average Shares Out $64.37 M $45.61 M $13.17 M $42.16 M $78.81 B $72.90 B $65.20 B $44.71 B
Weighted Average Shares Out Diluted $64.37 M $45.61 M $13.17 M $42.16 M $78.81 B $72.90 B $65.20 B $44.71 B
Link